Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Derma-Gold Cream is a pharmaceutical combination product designed to treat various types of skin infections. It comprises four active ingredients: Clobetasol, Neomycin, Miconazole, and Zinc Sulphate Monohydrate. Clobetasol, a potent corticosteroid, acts to reduce inflammation, redness, swelling, and itching by modulating the immune response and inhibiting the production of inflammatory mediators like prostaglandins. Neomycin is an aminoglycoside antibiotic that targets bacterial infections by inhibiting bacterial protein synthesis, thereby preventing the growth and proliferation of susceptible bacteria. Miconazole, an azole antifungal, combats fungal infections by interfering with the synthesis of ergosterol, a vital component of fungal cell membranes, which ultimately disrupts fungal cell integrity and inhibits growth. Zinc Sulphate Monohydrate contributes astringent and antiseptic properties, aiding in wound healing and preventing further microbial contamination. This multi-component formulation provides comprehensive action against inflammatory and infectious skin conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Derma-Gold Cream.